Recursion Pharmaceuticals Overview
- Founded
-
2013
- Status
-
Public
- Employees
-
500
- Stock Symbol
-
RXRX
- Investments
-
2
- Share Price
-
$7.26
- (As of Monday Closing)
Recursion Pharmaceuticals General Information
Description
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
Contact Information
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
- 41 South Rio Grande Street
- Salt Lake City, UT 84101
- United States
+1 (385) 000-0000
Recursion Pharmaceuticals Timeline
Recursion Pharmaceuticals Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $7.26 | $7.41 | $4.92 - $14.18 | $1.42B | 191M | 989K | -$1.36 |
Recursion Pharmaceuticals Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2022 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 1,059,019 | 1,059,019 | 2,321,561 | |
| Revenue | 39,681 | 39,681 | 10,000 | 3,413 |
| EBITDA | (233,919) | (233,919) | (175,195) | (82,039) |
| Net Income | (239,476) | (239,476) | (186,479) | (87,006) |
| Total Assets | 701,288 | 701,288 | 610,345 | 298,585 |
| Total Debt | 51,005 | 51,005 | 11,478 | 15,662 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Recursion Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Recursion Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Recursion Pharmaceuticals Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technolog
Biotechnology
Salt Lake City, UT
500
As of 2022
00.000
0.000
0000-00-00
000000000
00.000
000000
r adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna al
0000000000000
Branford, CT
000000
incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostr
0000 000000000
Nottingham, United Kingdom
000
As of 0000
000000000
Add Comparison
Recursion Pharmaceuticals Competitors (26)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| BioXcel | Corporation | Branford, CT | ||||
| 000000000 00000000 | Private Equity-Backed | Nottingham, United Kingdom | 000 | 000000000 | ||
| 0000000 | Venture Capital-Backed | Toronto, Canada | 00 | 000.00 | 00000 | 000.00 |
| 000000000000 | Formerly PE-Backed | London, United Kingdom | 000 | 00000 | 000000000 | 00000 |
| 000000 00000000000 | Corporation | Cambridge, MA | 000 | 00000 | 000000&0 | 00000 |
Recursion Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Recursion Pharmaceuticals Patents
Recursion Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220397565-A1 | Methods of screening and related systems | Pending | 10-Jun-2021 | 00000000000 | |
| US-20220380323-A1 | Heterocyclic compounds and related methods | Pending | 02-Mar-2021 | 000000000 | |
| US-20220262455-A1 | Determining the goodness of a biological vector space | Pending | 18-Feb-2021 | 0000000000 | |
| US-20220238181-A1 | Crispr guide selection | Pending | 27-Jan-2021 | 00000000 | |
| US-20220162601-A1 | High throughput gene editing system and method | Pending | 23-Nov-2020 | C12N9/22 | 0 |
Recursion Pharmaceuticals Executive Team (25)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Christopher Gibson Ph.D | Chief Executive Officer & Founder | ||
| Tina Larson | Chief Operating Officer, Operations & President | ||
| Michael Secora Ph.D | Chief Financial Officer, Finance & Chief Accounting Officer, Accounting | ||
| Ben Mabey | Chief Technology Officer | ||
| Ben Sukow | Director of Engineering |
Recursion Pharmaceuticals Board Members (14)
| Name | Representing | Role | Since |
|---|---|---|---|
| Alaa Halawa | Mubadala Investment Company | Board Observer | 000 0000 |
| Blake Borgeson Ph.D | Recursion Pharmaceuticals | Founder & Board Member | 000 0000 |
| Dean Li Ph.D | Recursion Pharmaceuticals | Co-Founder & Board Member | 000 0000 |
| James Hardiman | DCVC | Board Observer | 000 0000 |
| Lee Cooper JD | Leaps by Bayer | Board Observer | 000 0000 |
Recursion Pharmaceuticals Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Recursion Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Recursion Pharmaceuticals Investments & Acquisitions (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000 000000 | 22-Jun-2021 | 00000 0000 | 0000 | Biotechnology | |
| Vium | 28-Jul-2020 | Merger/Acquisition | Discovery Tools (Healthcare) | 000000000 |
Recursion Pharmaceuticals Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| 0000 | Discovery Tools (Healthcare) | San Mateo, CA | 0000 |
Recursion Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated October, 30, 2022
22.1 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,231
Rank
00.00
Percentile
Pharmaceuticals
Industry
00 of 899
Rank
00.0
Percentile
Biotechnology
Subindustry
00 of 401
Rank
0.00
Percentile
